key: cord-0906505-dm423qhy authors: Schwartz, Robert A.; Suskind, Robert M. title: Azithromycin and COVID‐19Prompt Early Use at First Signs of this Infection in Adults and Children An Approach Worthy of Consideration date: 2020-06-08 journal: Dermatol Ther DOI: 10.1111/dth.13785 sha: f67af23c4ce427a7e15002c867f2f8b2839971df doc_id: 906505 cord_uid: dm423qhy The devastating effects of the coronavirus designated severe acute respiratory syndrome coronavirus 2 (SARS‐Cov‐2) has led to urgent attempts to find effective therapeutic agents for inpatient and outpatient treatment of COVID‐19. Initial enthusiasm for the combination of hydroxychloroquine and azithromycin has abated. However, as a result of positive clinical experience with azithromycin used alone during the first few days of the flu‐like illness caused by this coronavirus, we recommend formal clinical trials using azithromycin early in the course of a COVID‐19 infection. There is one clinical trial initiated, the individually‐randomized, telemedicine‐based, “Azithromycin for COVID‐19 Treatment in Outpatients Nationwide (ACTION)” based at the University of California San Francisco. This placebo‐controlled trial is designed to determine the efficacy of a single 1.2 g dose of oral azithromycin to prevent COVID‐19 patient progression to hospitalization. We recommend formal clinical trials of azithromycin in its prepackaged form at the first sign of COVID‐19 infection in adults and children, using an initial adult dose of 500 mg followed by 250 mg per day for four days, a total cumulative dose of 1.5 g, and for children 5 to 18 years of age, 10 mg/kg on the first day followed by 5 mg/kg for four days. This article is protected by copyright. All rights reserved. Numerous clinical trials, including some utilizing inexpensive, widely available drugs, are under way against the SARS-Cov-2 virus now that COVID-19 has become a pandemic. There was initial enthusiasm for using hydroxychloroquine (HCQ) based on a French study which demonstrated a dramatic decrease in the nasopharyngeal viral load, with 93% of the subjects being negative by Day 8 (1) . This study was done on eighty, mildly affected, hospitalized patients. Each had been given a combination of 200 mg of HCQ three times a day for ten days, in addition to azithromycin, 500 mg on the first day, followed by 250 mg daily for the next four days. Both the clinical and virologic outcomes were positive. In patients who did not receive HCQ, viral clearance occurred in 12.5% of them; in those treated with HCQ alone viral clearance was 70%. However, in those treated with HCQ combined with azithromycin, viral clearance was 100%. Azithromycin alone was not studied. A follow-up retrospective study from this French group evaluated 1061 patients, 46.4% male, mean age 43.6 years, with an age range of 14-95 years. It reported a favorable clinical outcome with a virologic cure in 973 of the 1061 patients within ten days when using a combination of HCQ and azithromycin (2) . Other studies involving hospitalized patients have been less encouraging (3) . Unfortunately, HCQ is also associated with a high risk of significant cardiac and other adverse effects that include an occasional severe cutaneous adverse drug reaction called generalized pustular figurate erythema (3) (4) (5) . This article is protected by copyright. All rights reserved. An approach we have advocated since the inception of the pandemic is having a 5-day course of azithromycin ready for personal and family use at the first sign of COVID-19. One of us (RMS) has successfully treated more than fifty patients with flu-like symptoms without virologic testing, including children and one eightytwo-year-old male physician in addition to two women, eighty and sixty-five years of age, each of whom were documented to be SARS-Cov-2 positive. The treatment approach consisted of a five-day course of azithromycin, marketed as a five-day packaged regimen at a dose of 500 mg the first day and 250 mg for the remaining four days. Clinical improvement occurred in all patients within 24-48 hours of starting the antibiotic. There were no complications nor hospitalizations. Its use would have been precluded, however, if there had been a history of liver disease, heart disease, or allergies to azithromycin, erythromycin or any other macrolides. Azithromycin is a macrolide antibiotic used for acne vulgaris and for skin, respiratory and other infections (6) . It is one of the most commonly prescribed antibiotics in the US. It has shown in vitro activity against Zika and Ebola viruses and in vivo activity in the prevention of severe respiratory tract involvement in viral infections, probably owing to its immunomodulatory action (7) (8) (9) . Azithromycin inhibits protein synthesis and experimentally reduces inflammation and viral replication, possibly because cytokines and viruses are both made of proteins and utilize cellular ribosomes for protein translation. In addition, inhibiting virus production may reduce viral transmission to others, an important additional benefit. This article is protected by copyright. All rights reserved. Azithromycin is widely used and is generally considered a safe medication. There are, however, occasional adverse effects (10) . As with almost all antibiotics, diarrhea, nausea, vomiting and headache may ensue, as may occasional urticaria and other skin eruptions. Serious side effects are uncommon; however, they may include cardiac arrhythmias, especially in the elderly and in those with pre-existing QT interval prolongation, bradycardia, low serum potassium or magnesium, and those who are taking certain anti-arrhythmic drugs (5, 10) . In the search for a safe, effective treatment for individuals with early mild or moderate COVID-19, however, azithromycin is one of the most promising (11) . This article is protected by copyright. All rights reserved. We also encourage formal clinical trials with the prepackaged preparation of azithromycin which is administered at the first sign of a COVID-19 infection over a five-day period with 500 mg the first day and 250 mg for the remaining four days, for a total of 1.5 g for adults over 18 years of age, and for children 5 to 18 years of age, 10 mg/kg on the first day and 5 mg/kg for the following four days. Since COVID-19 patients may have a myriad of clinical signs and symptoms, some atypical, laboratory confirmation of COVID-19 is recommended. Patients should be examined carefully for coinfections with nosocomial respiratory pathogens, such as multi-drug resistant Candida auris and azithromycin-sensitive Mycoplasma pneumoniae, which may increase morbidity (14, 16) . This article is protected by copyright. All rights reserved. This plan for the early treatment of adults and children is a potentially efficient, cost-effective, readily available, easy-to-use, relatively safe, therapeutic option for most patients with early symptomatic COVID-19. In addition, it has the potential to contain the global pandemic, reduce concerns about a worldwide economic depression (17) , and normalize people's lives. Hydroxychloroquine and Azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Early treatment of COVID-19 patients with hydroxychloroquine and Azithromycin: A retrospective analysis of 1061 cases in Marseille, France Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis Generalized pustular figurate erythema. A newly delineated severe cutaneous drug reaction linked with This article is protected by copyright Recommendations for the measurement of the QT interval during the use of drugs for COVID-19 infection treatment Should Azithromycin be used to treat COVID-19? A rapid review. BJGP Open Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A(H1N1)pdm09 virus infection by interfering with virus internalization process Zika virus cell tropism in the developing human brain and inhibition by Azithromycin Azithromycin inhibits the replication of Zika virus Off-label" use of hydroxychloroquine, Azithromycin, lopinavir-This article is protected by copyright ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers Azithromycin for COVID-19 Treatment in Outpatients Nationwide COVID-19 with Dermatologic Manifestations and Implications: An Unfolding Conundrum Cutaneous Manifestations of a 21st Century Worldwide Fungal Epidemic Possibly Complicating the COVID-19 Pandemic to Jointly Menace Mankind COVID-19 and the urgent need to render spaces safer COVID-19 and mycoplasma pneumoniae coinfection Online ahead of print